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The human T-cell lymphotropic virus
type 1 (HTLV-1) is an oncogenic retrovi-
rus that is transmitted from mother to
child, particularly through prolonged
breastfeeding; between sexual partners
through unprotected intercourse; and
from donors to recipients through trans-
fusion and transplantation. Thirty-ﬁve
years after its discovery, screening for
HTLV-1 infection is at best patchy and
mostly nonexistent. There are 2 main rea-
sons for this: ﬁrst, the most recent esti-
mate of the prevalence of HTLV-1 is
5–10 million persons worldwide, with
the important caveat that 86% of the
global population is data poor in this re-
gard [1]; second, there is a perception
that disease related to this virus, which
has coexisted with humankind for
60 000 years, is uncommon. Whether
this reputation is justiﬁed requires up-
to-date and reliable sero- and clinical
epidemiology.
The lifetime risk, among carriers, of
adult-T-cell leukemia/lymphoma is 2%–
6% regardless of the region of study. How-
ever, for HTLV-1–associated myelopathy/
tropical spastic paraparesis (HAM/TSP),
more varied risks are reported with strong
hints that, apart from the route of infec-
tion, ethnicity and human leukocyte anti-
gen (HLA) types impact signiﬁcantly on
risk. Furthermore, HTLV-1 has been as-
sociated with a range of other inﬂamma-
torymanifestations affectingmany organs
but particularly eyes, lungs, and thyroid
and with increased susceptibility to
a number of infections, most notably
Strongyloides stercoralis hyperinfestation
syndrome. (Given the high mortality of
this latter condition, it is our policy to
screen all HTLV-1 carriers who have re-
sided in endemic areas for S. stercoralis).
These diseases are much less well recog-
nized even than HAM/TSP, with no data
on incidence or prevalence among carri-
ers. How, then, are we to judge the global
disease burden of HTLV-1 infection?
In this edition of Clinical Infectious
Diseases, Tanajura et al report on a longi-
tudinal study of 414 HTLV-1–infected
individuals in Brazil [2]. There are a
number of striking ﬁndings. First, among
study participants not previously diag-
nosed with HAM/TSP, 18.4% had, at
baseline assessment, symptoms, signs,
and investigations consistent with a deﬁ-
nite diagnosis of HAM/TSP. Second, an
additional 21%, again at baseline, had pos-
sible or probable HAM/TSP on the basis of
having either 1 motor sign consistent with
HAM/TSP or a neurogenic bladder (prob-
able) or a clinical diagnosis of HAM/TSP
without exclusion of other possible diag-
noses (possible). Third, during up to 8
years of follow-up, 5 subjects (all from
the probable HAM/TSP category) were di-
agnosed with deﬁnite HAM, an incidence
of 1.5%. Finally, very high incidences of a
range of neurological symptoms were doc-
umented, particularly sensory, including
upper limb, even though the median per-
person follow-up was only 2 years.
These ﬁndings are notable because
they differ by an order of magnitude
from most previous reports. Using data
from the mid-1980s, Kaplan et al estimat-
ed a 0.25% lifetime risk of HAM in
HTLV-1–infected Japanese individuals,
based on an average of 24.3 new cases re-
ported per year among approximately
794 800 seropositive individuals (3/
100 000 cases per annum) [3]. These
data have undoubtedly affected some
public health decisions outside Japan.
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However, in the Caribbean, Murphy et al
diagnosed myelopathy in 0.5% of HTLV-
1 carriers in a case-control study [4],
whereas Maloney et al estimated the life-
time risk of HAM/TSP at 1.9% with an
age-standardized annual incidence of
17.3 per 100 000 infected males and 24.7
per 100 000 infected females [5]. In the
United States, Murphy et al diagnosed my-
elopathy in 2.4% (4/166) newly diagnosed
HTLV-1–infected blood donors [6]; im-
portantly, this study included matched un-
infected controls. Although there is an
extensive literature on the inﬂuence of
HLA types on risk of disease associated
with HTLV-1 infection, especially through
impact on proviral load, and further evi-
dence of ethnic differences based on rates
of HAM/TSP according to tribe in a small
study from Zaire [7], the cross-sectional
prevalence reported from Brazil suggests a
lifetime risk in this population 10-fold
higher than previously reported. Is this due
togenetics orenvironmentor selectionbias?
The risk of HAM/TSP has been strongly
associated with proviral load and, in par-
ticular, with a cutoff of 1 HTLV-1 DNA
copy per 100 peripheral bloodmononucle-
ar cells (a proviral load of 1%) [8]. The Mi-
yazaki Cohort Study followed almost 2000
persons, among whom 27% were HTLV-1
infected, in a decade-long study and re-
ported paraesthesia, polyuria, and nocturia
to be twice as common among those in-
fected with HTLV-1. However, ﬁnding
no association with HTLV-1 proviral load
or strength of antibody response, they
concluded that HTLV-1 per se was not
causatively associated [9]. Similarly,
Tanajura et al found no association with
the frequency of sensory, bladder, or even
motor symptoms and HTLV-1 proviral
load even though up to 30% of the study
participants developed such symptoms
during follow-up. They did ﬁnd, however,
that carriers with HTLV-1 proviral loads of
>5%weremore likely to have demonstrated
deterioration in expanded disability status
score. Also at baseline, subjects diagnosed
with HAM/TSP had higher median
HTLV-1 proviral load (14.8%) than those
who were initially asymptomatic (2.5%),
with the probable/possible HAM/TSP sub-
set intermediate at 4%. It seems, therefore,
that the proviral load in this cohort may be
higher than in other cohorts that cite a me-
dian of 1% for asymptomatic carriers. Even
so, this does not fully account for the
exceptionally high prevalence and inci-
dence of deﬁnite HAM/TSP as assuming
a lifetime risk of HAM/TSP of up to 3%,
even subjects with proviral loads >1%
have only a 6% lifetime risk.
Because only 59% of the cohort was
identiﬁed through screening, with 32%
self-referred and the remainder identiﬁed
by the neurology service or by having
HTLV-1 in the family, further breakdown
of the data from the blood donors only
would be more comparable with other
studies and potentially contribute to un-
derstanding the role, if any, of selection
bias. In particular, the high rate of sen-
sory symptoms of the upper limbs are dif-
ﬁcult to explain from previous reports of
HAM/TSP and raise various possibilities,
including overreporting by study partici-
pants and the presence of additional fac-
tors or alternative etiologies.
It is difﬁcult to comment on the contri-
bution of environment (clinic and com-
munity), but there is now an urgent
need to test these ﬁndings in a new
study with HTLV-1–uninfected matched
controls. If conﬁrmed, at least in some in-
fected communities, the disease burden
of HTLV-1 is considerably higher than
previously reported, and this should
stimulate broader and more effective pre-
vention programs and greater interest
and ﬁnancial support for research into
the treatment of HAM/TSP.
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